Hydrogenology
Hydrogenology editorial study record

Effects of Hydrogen Gas Inhalation on Community-Dwelling Adults of Various Ages: A Single-Arm, Open-Label, Prospective Clinical Trial

Rahman MH et al. · Antioxidants (Basel). 2023;12(6):1241.

HumanInhaled H₂Published 2023
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Single-arm open-label prospective clinical trial

Research topic

Other neurological conditions

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Community-dwelling adults aged 40–70 years without diagnosed Alzheimer’s disease

Sample

54 screened and enrolled; 51 described in the analyzed cohort

Duration

30 minutes daily for 4 weeks

Intervention

2% H₂ in filtered air through a nasal cannula for 30 minutes daily

Hydrogen form

H₂ diluted in filtered ambient air — not Brown’s gas.

H₂ specification

2% H₂ + 98% filtered air.

H₂ flow

Not reported — device output and total gas flow were not stated, so absolute H₂ flow cannot be calculated.

O₂ delivered with H₂

No supplemental O₂ was reported; O₂ from filtered ambient air was present, but its absolute flow cannot be calculated.

Comparator

No control group

Reported, not endorsed

Outcomes and reported result

Outcomes measured

White-cell counts, oxidative-stress markers and multiple blood biomarkers associated with cognitive or neurodegenerative research

Reported result

Several blood biomarkers changed from baseline, while white-cell counts did not. The design cannot establish whether H₂ caused the changes or whether they represent clinical cognitive benefit.

Results-extraction completeness

Intervention, full methods, results, registry and funding statements checked in the open-access full text; gas flow remains unreported.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Uncontrolled before-and-after study with numerous biomarkers, no diagnosed Alzheimer’s population and no basis for inferring clinical efficacy. The device company assisted the study.

Applies directly to

Community-dwelling adults aged 40–70 under this short biomarker protocol; not patients with confirmed Alzheimer’s disease.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 37371971 · DOI: 10.3390/antiox12061241

Publisher access

Open-access full text is available through PMC and the publisher.

Extraction basis

Open-access PMC and publisher full texts plus PubMed record.

Record revision

2026-08-10